Your Article Summary
See Latest ArticlesExtended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study
Breast Cancer Research, 06/18/09
Markopoulos C et al. - In a study to compare the effect of exemestane on the lipid profile of postmenopausal pts with operable breast cancer in the adjuvant setting, to that of observation alone following completion of 5 to 7 yrs primary treatment with tamoxifen, it was found that exemestane lacks the beneficial effect of tamoxifen on lipids; however, sequential adjuvant treatment with exemestane in postmenopausal breast cancer pts following cessation of 5 to 7 yrs of tamoxifen does not appear to significantly alter the lipid profile vs an observational arm.
Methods- In this open-label, randomized, parallel group study, 411 postmenopausal pts with operable breast cancer who have been treated with tamoxifen for 5 to 7 yrs, were randomized to either 5 additional yrs of exemestane (25 mg/day; n=211) or observation only (n=200).
- Assessments of total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total serum triglycerides (TRG) were performed at baseline and then during each follow up visit, performed at either 6 or 12 mos according to the center's clinical practice, until completing 24 mos in the study.
- TC and LDL levels increased significantly across time for both arms; TC increase was more pronounced for the observation arm and that was sustained up to 24 mos.
- HDL levels decreased significantly across time for the exemestane arm, while no significant change was detected across time for the observation arm.
- Triglyceride levels decreased significantly across time on both arms with no difference detected in changes from baseline between exemestane and observation arm.
Related Articles
Testosterone and biological characteristics of breast cancers in postmenopausal women
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 90%
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 89%
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
Annals of Oncology, 11/04/09
Relevance Score: 89%
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
Annals of Oncology, 10/20/09
Relevance Score: 89%
Original contribution: association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
JAMA, 10/07/09
Relevance Score: 89%
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Quantification of noncalcified coronary atherosclerotic plaques with Dual Source Computed Tomography: comparison to intravascular ultrasound
Heart, 11/29/09
What is the clinical usefulness of the metabolic syndrome? The Casale Monferrato study
Journal of Hypertension, 11/29/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09